➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Medtronic
Mallinckrodt
Boehringer Ingelheim
AstraZeneca

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DEXLANSOPRAZOLE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Dexlansoprazole

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00251693 ↗ Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis Completed Takeda Phase 3 2005-12-01 The purpose of this study is to assess the efficacy and safety of 8 weeks of once-daily (QD) treatment with dexlansoprazole modified release (MR) 60 mg or 90 mg or lansoprazole 30 mg in healing subjects with endoscopically proven erosive esophagitis.
NCT00251719 ↗ Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis Completed Takeda Phase 3 2005-12-01 This is a study to assess the efficacy and safety of 8 weeks of treatment with Dexlansoprazole modified release (MR)(60 mg daily and 90 mg daily) compared to Lansoprazole (30 mg daily) in healing subjects with endoscopically proven erosive esophagitis.
NCT00251745 ↗ Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn Completed Takeda Phase 3 2005-12-01 The purpose of this study is to assess the efficacy and safety of daily treatment with Dexlansoprazole modified release (MR) (60 mg or 90 mg once daily [QD]) compared to placebo QD in relief of daytime and nighttime heartburn over 4 weeks in subjects with gastroesophageal reflux disease (GERD).
NCT00251758 ↗ Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn Completed Takeda Phase 3 2005-12-01 The purpose of this study is to assess the efficacy and safety of daily treatment with Dexlansoprazole modified release (MR) (60 mg or 90 mg once daily [QD]) compared to placebo QD in relief of daytime and nighttime heartburn over 4 weeks in subjects with gastroesophageal reflux disease (GERD).
NCT00255151 ↗ Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis Completed Takeda Phase 3 2006-01-01 The purpose of this study is to assess the ability of once-daily (QD) treatment with Dexlansoprazole modified-release (MR) 60 mg and 90 mg and placebo in maintaining healing of erosive esophagitis (EE).
NCT00255164 ↗ Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis Completed Takeda Phase 3 2006-01-01 The purpose of this study is to assess the ability of once-daily (QD) treatment with Dexlansoprazole modified-release (MR) 60 mg and 90 mg and placebo in maintaining healing of erosive esophagitis (EE).
NCT00255190 ↗ Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn Completed Takeda Phase 3 2006-01-01 The purpose of this study is to determine the long-term safety profile of daily treatment with dexlansoprazole MR in subjects with gastroesophageal reflux disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Dexlansoprazole

Condition Name

Condition Name for Dexlansoprazole
Intervention Trials
Gastroesophageal Reflux Disease 11
Gastroesophageal Reflux 5
Esophagitis, Reflux 5
Esophagitis, Peptic 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Dexlansoprazole
Intervention Trials
Gastroesophageal Reflux 23
Esophagitis 10
Esophagitis, Peptic 7
Heartburn 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Dexlansoprazole

Trials by Country

Trials by Country for Dexlansoprazole
Location Trials
United States 458
Mexico 17
Canada 12
India 9
Brazil 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Dexlansoprazole
Location Trials
California 19
Ohio 17
Arizona 17
Texas 17
Illinois 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Dexlansoprazole

Clinical Trial Phase

Clinical Trial Phase for Dexlansoprazole
Clinical Trial Phase Trials
Phase 4 11
Phase 3 13
Phase 2/Phase 3 1
[disabled in preview] 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Dexlansoprazole
Clinical Trial Phase Trials
Completed 25
Not yet recruiting 7
Recruiting 5
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Dexlansoprazole

Sponsor Name

Sponsor Name for Dexlansoprazole
Sponsor Trials
Takeda 31
University of Karachi 1
Kaohsiung Medical University 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Dexlansoprazole
Sponsor Trials
Industry 34
Other 26
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Express Scripts
Mallinckrodt
AstraZeneca
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.